Porton Pharma Solutions R&D and Manufacturing Facility at Mengeš Campus

terminated

Porton Pharma Solutions planned to invest 50 million euros to establish R&D and manufacturing facilities at Novartis' Mengeš campus in Slovenia. The facility was intended to provide services around process development for GMP intermediates and active pharmaceutical ingredients, development of analytical methods, and large-scale production throughout a drug's life cycle. The project included the opening of the 'B31' R&D facility in May 2024 and the completion of the main 'B30' production building construction in December 2025. However, regulatory issues with B30's early paperwork led to suspension of investment and construction progress, resulting in Novartis unilaterally terminating the plant leasing contract and demanding Porton vacate the facility within 90 days as of May 13, 2026.